Sanos Clinic | Herlev, Denmark

Research site

(Unclaimed)

Location

Hovedgade 82, Herlev, Copenhagen, Denmark

Site insights

Top conditions

Top treatments

AMZ001

LY3819469

Deucravacitinib

Olpasiran

Muvalaplin

JTA-004

Ruxolitinib

Evolocumab

Ustekinumab

LY3841136

Parent organization

This site is a part of Sanos Clinic

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 18 total trials

Locations recently updated

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in children (6 to \< 12 years old) with nonsegmental vitiligo.

Enrolling

NonSegmental Vitiligo

Drug: Vehicle Cream

Drug: Ruxolitinib Cream

Locations recently updated

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Active, not recruiting

Atherosclerotic Cardiovascular Disease (ASCVD)

Elevated Lp(a)

Drug: Lepodisiran Sodium

Drug: Placebo

Locations recently updated

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) (MOVE-Lp(a))

The purpose of this study is to evaluate the efficacy of muvalaplin in reducing cardiovascular risk in participants with high lipoprotein(a) who have...

Enrolling

Atherosclerotic Cardiovascular Disease (ASCVD)

Elevated Lp(a)

Drug: Placebo

Drug: Muvalaplin

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight (ENLIGHTEN-4)

The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralint...

Enrolling

Overweight or Obesity

Osteoarthritis

Drug: Placebo

Drug: Eloralintide

Efficacy and Safety Trial of PTP-001 (MOTYS) for Symptomatic Knee Osteoarthritis

Evaluation of safety, tolerability and efficacy of a single intra-articular (IA) injection of PTP-001, an allogeneic placental tissue particulate, in...

Active, not recruiting

Osteoarthritis, Knee

Biological: PTP-001

Other: Placebo control

Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-1)

The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.

Active, not recruiting

Obesity

Drug: Placebo

Drug: Maridebart Cafraglutide

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

A study to evaluate the long-term safety of Deucravacitinib versus Ustekinumab in participants with psoriasis

Enrolling

Plaque Psoriasis

Drug: Ustekinumab

Drug: Deucravacitinib

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial

The primary objective of this trial is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (C...

Active, not recruiting

Atherosclerotic Cardiovascular Disease

Drug: Olpasiran

Drug: Placebo

Locations recently updated

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent...

Active, not recruiting

Atherosclerotic Cardiovascular Disease (ASCVD)

Chronic Kidney Disease (CKD)

Drug: Retatrutide

Drug: Placebo